<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31924810</article-id><article-id pub-id-type="pmc">6954113</article-id><article-id pub-id-type="publisher-id">56695</article-id><article-id pub-id-type="doi">10.1038/s41598-019-56695-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genetic Variants Associated with Chronic Kidney Disease in a Spanish Population</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Corredor</surname><given-names>Zuray</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Filho</surname><given-names>Miguel In&#x000e1;cio da Silva</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rodr&#x000ed;guez-Ribera</surname><given-names>Lara</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vel&#x000e1;zquez</surname><given-names>Antonia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6938-1233</contrib-id><name><surname>Hern&#x000e1;ndez</surname><given-names>Alba</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Catalano</surname><given-names>Calogerina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hemminki</surname><given-names>Kari</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Coll</surname><given-names>Elisabeth</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Diaz</surname><given-names>Juan Manuel</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ballarin</surname><given-names>Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Vall&#x000e9;s Prats</surname><given-names>Mart&#x000ed;</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Calabia Mart&#x000ed;nez</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>F&#x000f6;rsti</surname><given-names>Asta</given-names></name><address><email>A.Foersti@dkfz-heidelberg.de</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7891-357X</contrib-id><name><surname>Marcos</surname><given-names>Ricard</given-names></name><address><email>ricard.marcos@uab.es</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Pastor</surname><given-names>Susana</given-names></name><address><email>susana.pastor@uab.es</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.7080.f</institution-id><institution>Grup de Mutag&#x000e8;nesi, Departament de Gen&#x000e8;tica i de Microbiologia, Edifici C, Universitat Aut&#x000f2;noma de Barcelona, </institution></institution-wrap>Bellaterra, Cerdanyola del Vall&#x000e8;s Spain </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution>Division of Molecular Genetic Epidemiology, </institution><institution>German Cancer Research Center (DKFZ), </institution></institution-wrap>Heidelberg, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9314 1427</institution-id><institution-id institution-id-type="GRID">grid.413448.e</institution-id><institution>Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Carlos III Institute of Health, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1767 1951</institution-id><institution-id institution-id-type="GRID">grid.418813.7</institution-id><institution>Fundaci&#x000f3; Puigvert, Nephology Department, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1837 4818</institution-id><institution-id institution-id-type="GRID">grid.411295.a</institution-id><institution>Hospital Josep Trueta, </institution></institution-wrap>Girona, Spain </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>10</volume><elocation-id>144</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2019</year></date><date date-type="accepted"><day>11</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Chronic kidney disease (CKD) patients have many affected physiological pathways. Variations in the genes regulating these pathways might affect the incidence and predisposition to this disease. A total of 722 Spanish adults, including 548 patients and 174 controls, were genotyped to better understand the effects of genetic risk loci on the susceptibility to CKD. We analyzed 38 single nucleotide polymorphisms (SNPs) in candidate genes associated with the inflammatory response (interleukins <italic>IL-1A</italic>, <italic>IL-4</italic>, <italic>IL-6</italic>, <italic>IL-10</italic>, <italic>TNF-&#x003b1;</italic>, <italic>ICAM-1)</italic>, fibrogenesis (<italic>TGFB1</italic>), homocysteine synthesis (<italic>MTHFR</italic>), DNA repair (<italic>OGG1</italic>, <italic>MUTYH</italic>, <italic>XRCC1</italic>, <italic>ERCC2</italic>, <italic>ERCC4</italic>), renin-angiotensin-aldosterone system (<italic>CYP11B2</italic>, <italic>AGT</italic>), phase-II metabolism <italic>(GSTP1</italic>, <italic>GSTO1</italic>, <italic>GSTO2)</italic>, antioxidant capacity (<italic>SOD1</italic>, <italic>SOD2</italic>, <italic>CAT</italic>, <italic>GPX1</italic>, <italic>GPX3</italic>, <italic>GPX4</italic>), and some other genes previously reported to be associated with CKD (<italic>GLO1</italic>, <italic>SLC7A9</italic>, <italic>SHROOM3</italic>, <italic>UMOD</italic>, <italic>VEGFA</italic>, <italic>MGP</italic>, <italic>KL</italic>). The results showed associations of <italic>GPX1</italic>, <italic>GSTO1</italic>, <italic>GSTO2</italic>, <italic>UMOD</italic>, and <italic>MGP</italic> with CKD. Additionally, associations with CKD related pathologies, such as hypertension (<italic>GPX4</italic>, <italic>CYP11B2</italic>, <italic>ERCC4</italic>), cardiovascular disease, diabetes and cancer predisposition (<italic>ERCC2</italic>) were also observed. Different genes showed association with biochemical parameters characteristic for CKD, such as creatinine (<italic>GPX1</italic>, <italic>GSTO1</italic>, <italic>GSTO2</italic>, <italic>KL</italic>, <italic>MGP</italic>), glomerular filtration rate (<italic>GPX1</italic>, <italic>GSTO1</italic>, <italic>KL</italic>, <italic>ICAM-1</italic>, <italic>MGP</italic>), hemoglobin (<italic>ERCC2</italic>, <italic>SHROOM3</italic>), resistance index erythropoietin (<italic>SOD2</italic>, <italic>VEGFA</italic>, <italic>MTHFR</italic>, <italic>KL</italic>), albumin (<italic>SOD1</italic>, <italic>GSTO2</italic>, <italic>ERCC2</italic>, <italic>SOD2</italic>), phosphorus (<italic>IL-4</italic>, <italic>ERCC4 SOD1</italic>, <italic>GPX4</italic>, <italic>GPX1</italic>), parathyroid hormone (<italic>IL-1A</italic>, <italic>IL-6</italic>, <italic>SHROOM3</italic>, <italic>UMOD</italic>, <italic>ICAM-1</italic>), C-reactive protein (<italic>SOD2</italic>, <italic>TGFB1</italic>,<italic>GSTP1</italic>, <italic>XRCC1)</italic>, and ferritin (<italic>SOD2</italic>, <italic>GSTP1</italic>, <italic>SLC7A9</italic>, <italic>GPX4</italic>). To our knowledge, this is the second comprehensive study carried out in Spanish patients linking genetic polymorphisms and CKD.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Genetic association study</kwd><kwd>End-stage renal disease</kwd></kwd-group><funding-group><award-group><funding-source><institution>Fondo Investigacion Sanitaria FIS, PI12/02559)</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Chronic kidney disease (CKD) is becoming a major public health problem worldwide. CKD is defined as a progressive loss of renal function, measured by a decline in glomerular filtration rate (GFR&#x02009;&#x0003c;&#x02009;60&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>)<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, which is typically associated with irreversible pathological changes within the kidney. This pathology has a complicated interrelationship with other diseases<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. Diabetes (DM) and hypertension (HT) are the primary risk factors for CKD<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, and CKD is also associated with cardiovascular morbidity and mortality<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>, even in early stages and in young patients<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par3">CKD patients are also characterized by a high genomic instability<sup><xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref></sup>. This instability could be translated to high levels of genetic damage measured by the incidence of chromosomal damage (micronuclei) when their cells are challenged with ionizing radiation<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> and could be either the cause or the consequence of renal pathologies. In addition, it has been observed that CKD patients repair less efficiently DNA damage<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par4">CKD patients present increased levels of C-reactive protein (CRP), which is indicative of an inflammatory status<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Oxidative stress is also a characteristic usually shown by CKD patients<sup><xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref></sup>. Variants in genes regulating such different pathways may affect CKD incidence and/or its progression. In this context recent genome-wide association studies (GWASs) on large European populations have identified novel genetic risk single-nucleotide polymorphisms (SNPs) associated with different CKD related pathologies like hypertension<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, coronary artery disease<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, subclinical vascular disease<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, and kidney functional traits in CKD patients<sup><xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref></sup>. Other studies have shown an overlap between genetic variants underpinning kidney traits and cardiovascular pathologies<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>.</p><p id="Par5">Aiming to determine possible associations between allelic variants and susceptibility to CKD, we selected and genotyped 38 SNPs from 31 candidate genes related directly to CKD and to the additional diseases (mainly hypertension, diabetes and inflammation, among others) in a Spanish population.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Population</title><p id="Par6">Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> shows some general characteristics of the individuals under study. Among CKD patients there were more men than women, reflecting the well-known higher incidence of CKD in males. As expected, statistically significant differences were observed between cases and controls for different parameters related to the pathology. The differences were highly significant (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) for the levels of age, creatinine, glomerular filtration rate, hemoglobin, albumin, parathyroid hormone, C-reactive protein, uric acid, proteinuria, and urea. The number of samples included in some comparisons is too small to allow definite conclusions. The CKD patients show the main characteristics of the CKD populations as are reflexed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The group of patients have more individuals affected by hypertension (91.5% <italic>vs</italic> a 29% in the control group), and with <italic>diabetes mellitus</italic> (DM) (32% <italic>vs</italic> a 7.5% in the control group). Regarding the cardiovascular disease (CVD), it could be said that 45% of the CKD patients presented CVD. Unfortunately, for the control group, we only have 53% of the answers, and of these nobody present CVD,<table-wrap id="Tab1"><label>Table 1</label><caption><p>Description of the study population. Differences in biochemical and clinical parameters of the studied groups are indicated.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic<sup>a</sup></th><th>Controls N&#x02009;=&#x02009;174 (N) mean&#x02009;&#x000b1;&#x02009;SD</th><th>Cases N&#x02009;=&#x02009;548 (N) mean&#x02009;&#x000b1;&#x02009;SD</th></tr></thead><tbody><tr><td>Age (years)</td><td>(169) 56.06&#x02009;&#x000b1;&#x02009;15.31</td><td>(547) 66.34&#x02009;&#x000b1;&#x02009;13.40***</td></tr><tr><td>Gender (men/women)</td><td>105 (61%)/67 (39%) %0/67</td><td>338 (62%)/210 (38%)</td></tr><tr><td>Creatinine (45&#x02013;80 &#x000b5;mol/L)<sup>a</sup></td><td>(169) 69.86&#x02009;&#x000b1;&#x02009;14.36</td><td>(184) 200.95&#x02009;&#x000b1;&#x02009;92.92***</td></tr><tr><td>Glomerular Filtration Rate (&#x0003e;60&#x02009;mL/min/1.75&#x02009;m<sup>2</sup>)</td><td>(169) 86.82&#x02009;&#x000b1;&#x02009;6.98</td><td>(184) 31.22&#x02009;&#x000b1;&#x02009;13.69***</td></tr><tr><td>Erythropoietin/month (&#x000b5;g Darbepoetin/month)</td><td>ND</td><td>(400) 207.61&#x02009;&#x000b1;&#x02009;689.91</td></tr><tr><td>Erythropoietin Resistance Index (&#x0003c;10)</td><td>ND</td><td>(379) 13.50&#x02009;&#x000b1;&#x02009;37.45</td></tr><tr><td>Hemoglobin (120&#x02013;160&#x02009;g/L)</td><td>(96) 144.18&#x02009;&#x000b1;&#x02009;11.96</td><td>(539) 128.41&#x02009;&#x000b1;&#x02009;18.23***</td></tr><tr><td>Glucose (4&#x02013;5.8 &#x000b5;mol/L)</td><td>(113) 5.86&#x02009;&#x000b1;&#x02009;1.93</td><td>(412) 5.60&#x02009;&#x000b1;&#x02009;1.85*</td></tr><tr><td>Cholesterol (3.20&#x02013;5.20&#x02009;mmol/L)</td><td>(86) 5.22&#x02009;&#x000b1;&#x02009;1.04</td><td>(542) 4.48&#x02009;&#x000b1;&#x02009;1.16**</td></tr><tr><td>Triglycerides (0.30&#x02013;1.40&#x02009;mmol/L)</td><td>(84) 1.34&#x02009;&#x000b1;&#x02009;1.19</td><td>(542) 1.50&#x02009;&#x000b1;&#x02009;0.79**</td></tr><tr><td>Albumin (37&#x02013;47&#x02009;g/L)</td><td>(66) 44.06&#x02009;&#x000b1;&#x02009;4.28</td><td>(405) 40.70&#x02009;&#x000b1;&#x02009;4.52***</td></tr><tr><td>Calcium (2.1&#x02013;2.55&#x02009;mmol/L)</td><td>(70) 2.33&#x02009;&#x000b1;&#x02009;0.11</td><td>(542) 2.29&#x02009;&#x000b1;&#x02009;0.25</td></tr><tr><td>Phosphorus (0.8&#x02013;1.3&#x02009;mmol/L)</td><td>(68) 1.07&#x02009;&#x000b1;&#x02009;0.14</td><td>(542) 1.30&#x02009;&#x000b1;&#x02009;0.40**</td></tr><tr><td>Parathyroid hormone (7&#x02013;53&#x02009;ng/L)</td><td>(25) 61.23&#x02009;&#x000b1;&#x02009;23.58</td><td>(401) 190.19&#x02009;&#x000b1;&#x02009;179.09***</td></tr><tr><td>Ferritin (25&#x02013;250&#x02009;&#x000b5;g/L)</td><td>(3) 88.56&#x02009;&#x000b1;&#x02009;49.32</td><td>(325) 245.87&#x02009;&#x000b1;&#x02009;257.66</td></tr><tr><td>C-Reactive Protein (&#x0003c;10&#x02009;mg/L)</td><td>(13) 2.80&#x02009;&#x000b1;&#x02009;3.21</td><td>(362) 10.16&#x02009;&#x000b1;&#x02009;19.40*</td></tr><tr><td>Uric acid (210&#x02013;420 &#x000b5;mol/L)</td><td>(98) 302.54&#x02009;&#x000b1;&#x02009;85.50</td><td>(286) 385.80&#x02009;&#x000b1;&#x02009;109.60***</td></tr><tr><td>Proteinuria/24&#x02009;h (&#x0003c;0.15&#x02009;g/L)</td><td>(116) 0.14&#x02009;&#x000b1;&#x02009;0.73</td><td>(165) 0.81&#x02009;&#x000b1;&#x02009;1.43***</td></tr><tr><td>Urea (2.5&#x02013;7 Mmol/L)</td><td>(56) 5.67&#x02009;&#x000b1;&#x02009;1.63</td><td>(179) 15.32&#x02009;&#x000b1;&#x02009;6.88***</td></tr><tr><td>Hba1c glycosylated hemoglobin (&#x0003c;5.7%)</td><td>(10) 5.18&#x02009;&#x000b1;&#x02009;2.43</td><td>(158) 4.80&#x02009;&#x000b1;&#x02009;1.62</td></tr><tr><td>Fibrinogen (2&#x02013;4 &#x000b5;mol/L)</td><td>(2) 4.35&#x02009;&#x000b1;&#x02009;1.11</td><td>(91) 4.47&#x02009;&#x000b1;&#x02009;0.98</td></tr><tr><td>Hypertension (yes/no)</td><td>27 (29%)/66 (71%)</td><td>498 (91.5%)/46 (8.5%)***</td></tr><tr><td><italic>Diabetes Mellitus</italic> (yes/no)</td><td>7 (7.5%)/86 (92.5%)</td><td>174 (32%)/370 (68%)***</td></tr></tbody></table><table-wrap-foot><p>Mann-Whitney test; cases vs controls; ***P&#x02009;&#x0003c;&#x02009;0.001, **P&#x02009;&#x0003c;&#x02009;0.01, *P&#x02009;&#x0003c;&#x02009;0.05. ND: no data. <sup>a</sup>normal values are shown in parentheses.</p></table-wrap-foot></table-wrap></p><p id="Par7">The slight differences in the numbers of patients reported for different parameters are due to their absence in the questionnaires, or to failure in the corresponding analysis.</p></sec><sec id="Sec4"><title>SNPs associated with CKD</title><p id="Par8">General information about the 38 SNPs included in the study, with their allelic frequencies and their location in the genome is described in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. As indicated, we used alternative SNPs in strong linkage disequilibrium (LD) with the selected one, when no assay corresponding to the originally selected SNP was available.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Description of the SNPs selected for this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Function group</th><th>Gene</th><th>SNP original</th><th>SNP alternative</th><th>LD (r<sup>2</sup>)</th><th>Chr</th><th>Position (NCBI dbSNP GRCh38)</th><th>Consequence of the original SNP*</th><th>Minor allele</th><th>Major allele</th><th>Minor allele frequency (NCBI dbSNP)</th></tr></thead><tbody><tr><td/><td><italic>GLO1</italic></td><td>rs386572987</td><td>rs4746</td><td>1.00</td><td>6</td><td>38682852</td><td>missense<sup>a</sup> Glu111Ala</td><td>G</td><td>T</td><td>0.2873</td></tr><tr><td rowspan="3">Associated with CKD</td><td><italic>SLC7A9</italic></td><td>rs12460876</td><td/><td/><td>19</td><td>32865985</td><td>intron variant</td><td>C</td><td>T</td><td>0.4235</td></tr><tr><td><italic>SHROOM3</italic></td><td>rs17319721</td><td/><td/><td>4</td><td>76447694</td><td>intron variant</td><td>A</td><td>G</td><td>0.2238</td></tr><tr><td><italic>UMOD</italic></td><td>rs12917707</td><td/><td/><td>16</td><td>20356368</td><td>66&#x02009;bp 5&#x02032; of UMOD</td><td>T</td><td>G</td><td>0.0982</td></tr><tr><td/><td><italic>VEGFA</italic></td><td>rs881858</td><td/><td/><td>6</td><td>43838872</td><td>13&#x02009;kb 3&#x02032; of RP11&#x02013;344J7.2</td><td>G</td><td>A</td><td>0.3626</td></tr><tr><td/><td><italic>IL-1A</italic></td><td>rs1800587</td><td>rs17561</td><td>0.99</td><td>2</td><td>112779646</td><td>5&#x02032;-UTR</td><td>A</td><td>C</td><td>0.2175</td></tr><tr><td>Cytokines<sup>c</sup></td><td><italic>IL-4</italic></td><td>rs2243250</td><td>rs2070874</td><td>0.99</td><td>5</td><td>132674018</td><td>2KB 5&#x02032;IL-4 <sup>a</sup></td><td>T</td><td>C</td><td>0.4012</td></tr><tr><td/><td><italic>IL-6</italic></td><td>rs1800795</td><td>rs1800797</td><td>0.97</td><td>7</td><td>22726602</td><td>intron variant</td><td>A</td><td>G</td><td>0.1382</td></tr><tr><td/><td><italic>IL-10</italic></td><td>rs1800896</td><td/><td/><td>1</td><td>206773552</td><td>1.1&#x02009;kb 5&#x02032; of IL10</td><td>C</td><td>T</td><td>0.2722</td></tr><tr><td/><td><italic>TNF-&#x003b1;</italic></td><td>rs1800629</td><td/><td/><td>6</td><td>31575254</td><td>312&#x02009;bp 5&#x02032; of TNF</td><td>A</td><td>G</td><td>0.0903</td></tr><tr><td/><td><italic>ICAM-1</italic></td><td>rs5498</td><td/><td/><td>19</td><td>10285007</td><td>missense Glu469lys</td><td>G</td><td>A</td><td>0.3588</td></tr><tr><td rowspan="2">Renin-angiotensin-aldosterone<sup>c</sup></td><td><italic>CYP11B2</italic></td><td>rs1799998</td><td/><td/><td>8</td><td>142918184</td><td>340&#x02009;bp 5&#x02032; of CYP11B2</td><td>G</td><td>A</td><td>0.3472</td></tr><tr><td><italic>AGT</italic></td><td>rs5050</td><td/><td/><td>1</td><td>230714140</td><td>5&#x02032; UTR</td><td>G</td><td>T</td><td>0.1759</td></tr><tr><td>Fibrogenesis<sup>c</sup></td><td><italic>TGFB1</italic></td><td>rs1800470</td><td/><td/><td>19</td><td>41353016</td><td>Missense Pro10Leu</td><td>G</td><td>A</td><td>0.4547</td></tr><tr><td/><td/><td>rs1800468</td><td/><td/><td>19</td><td>41354682</td><td>3&#x02032;UTR</td><td>T</td><td>C</td><td>0.0413</td></tr><tr><td/><td/><td>rs1800469</td><td/><td/><td>19</td><td>41354391</td><td>intron variant</td><td>A</td><td>G</td><td>0.368</td></tr><tr><td>Homocysteine synthesis</td><td>MTHFR</td><td>rs1801133</td><td/><td/><td>1</td><td>11796321</td><td>missense</td><td>T</td><td>C</td><td>0.2454</td></tr><tr><td rowspan="7">Antioxidant enzymes</td><td><italic>SOD1</italic></td><td>rs17880135</td><td/><td/><td>21</td><td>31669690</td><td>758&#x02009;bp 3&#x02032; of SOD1</td><td>G</td><td>T</td><td>0.0276</td></tr><tr><td><italic>SOD1</italic></td><td>rs1041740</td><td/><td/><td>21</td><td>31667849</td><td>intron variant</td><td>T</td><td>C</td><td>0.2428</td></tr><tr><td><italic>SOD1</italic></td><td>rs202446</td><td/><td/><td>21</td><td>31656328</td><td>intron variant<sup>a</sup></td><td>T</td><td>G</td><td>0.0755</td></tr><tr><td><italic>SOD2</italic></td><td>rs4880</td><td/><td/><td>6</td><td>159692840</td><td>missense Val16Ala</td><td>G</td><td>A</td><td>0.4107</td></tr><tr><td><italic>CAT</italic></td><td>rs1001179</td><td/><td/><td>11</td><td>34438684</td><td>240&#x02009;bp 5&#x02032; of CAT</td><td>T</td><td>C</td><td>0.1256</td></tr><tr><td><italic>GPX1</italic></td><td>rs1050450</td><td>rs17080528</td><td>0.98</td><td>3</td><td>49352409</td><td>Downstream gene variant<sup>b</sup></td><td>T</td><td>C</td><td>0.2175</td></tr><tr><td><italic>GPX3</italic></td><td>rs870406</td><td/><td/><td>5</td><td>151021040</td><td>intron variant</td><td>A</td><td>G</td><td>0.0974</td></tr><tr><td/><td><italic>GPX4</italic></td><td>rs713041</td><td/><td/><td>19</td><td>1106616</td><td>synonymous</td><td>T</td><td>C</td><td>0.401</td></tr><tr><td>NER</td><td><italic>ERCC2 (XPD)</italic></td><td>rs1799793</td><td/><td/><td>19</td><td>45364001</td><td>Missense Asp312Asn</td><td>T</td><td>C</td><td>0.1945</td></tr><tr><td/><td><italic>ERCC2</italic></td><td>rs171140</td><td/><td/><td>19</td><td>45361744</td><td>intron variant</td><td>C</td><td>A</td><td>0.367</td></tr><tr><td/><td><italic>ERCC2</italic></td><td>rs13181</td><td/><td/><td>19</td><td>45351661</td><td>missense 500pb 3&#x02032; of ERCC2</td><td>G</td><td>T</td><td>0.2366</td></tr><tr><td/><td><italic>ERCC4</italic></td><td>rs3136166</td><td/><td/><td>16</td><td>13938236</td><td>intron variant</td><td>G</td><td>T</td><td>0.4249</td></tr><tr><td rowspan="3">BER</td><td><italic>OGG1</italic></td><td>rs1052133</td><td/><td/><td>3</td><td>9757089</td><td>missense Ser326Cys</td><td>G</td><td>C</td><td>0.3021</td></tr><tr><td><italic>MUTYH</italic></td><td>rs3219489</td><td/><td/><td>1</td><td>45331833</td><td>missense Gln338His</td><td>G</td><td>C</td><td>0.3135</td></tr><tr><td><italic>XRCC1</italic></td><td>rs25487</td><td/><td/><td>19</td><td>43551574</td><td>missense Gln399Arg</td><td>T</td><td>C</td><td>0.2604</td></tr><tr><td>Phase-II metabolism</td><td><italic>GSTP1</italic></td><td>rs1695</td><td>rs749174</td><td>0.92</td><td>11</td><td>67585782</td><td>missense Ile105Val</td><td>A</td><td>G</td><td>0.2438</td></tr><tr><td/><td><italic>GSTO1</italic></td><td>rs4925</td><td>rs2164624</td><td>0.93</td><td>10</td><td>104253687</td><td>intron variant<sup>b</sup></td><td>A</td><td>G</td><td>0.1879</td></tr><tr><td/><td><italic>GSTO2</italic></td><td>rs156697</td><td/><td/><td>10</td><td>104279427</td><td>missense Asn142Asp</td><td>G</td><td>A</td><td>0.4407</td></tr><tr><td rowspan="2">Genes related with mortality in hemolyzed s</td><td><italic>MGP</italic></td><td>rs4236</td><td/><td/><td>12</td><td>14882147</td><td>missense Thr83Ala</td><td>C</td><td>T</td><td>0.3854</td></tr><tr><td><italic>KL</italic></td><td>rs1207568</td><td/><td/><td>13</td><td>33016046</td><td>22&#x02009;bp 5&#x02032; of KL</td><td>A</td><td>G</td><td>0.1601</td></tr><tr><td><italic>patients</italic></td><td><italic>KL</italic></td><td>rs577912</td><td/><td/><td>13</td><td>33036014</td><td>intron variant</td><td>T</td><td>G</td><td>0.1953</td></tr></tbody></table><table-wrap-foot><p>Chr. chromosome; *according to Haploreg; LD linkage disequilibrium; <sup>a</sup><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed">http://www.ncbi.nlm.nih.gov/pubmed</ext-link>. <sup>b</sup><ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/index.html">http://www.ensembl.org/index.html</ext-link>; <sup>c</sup>related to pathological process characteristic of chronic kidney disease.</p></table-wrap-foot></table-wrap></p><p id="Par9">Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows the observed associations (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) between the candidate SNPs and CKD susceptibility in the entire study population. When the analysis was adjusted for age and gender, three SNPs showed an association under the dominant model. These SNPs were rs17080528 in the <italic>GPX1</italic> gene, that encodes one of the most important antioxidant enzymes in humans (OR&#x02009;=&#x02009;1.87, <italic>P</italic>&#x02009;=&#x02009;0.001) and rs2164624 and rs156697 in the <italic>GSTO1</italic> and <italic>GSTO2</italic> genes, both involved in the metabolism of xenobiotics and carcinogens (OR&#x02009;=&#x02009;0.50, <italic>P</italic>&#x02009;=&#x02009;0.0007, and OR&#x02009;=&#x02009;0.57, <italic>P</italic>&#x02009;=&#x02009;0.013, respectively). For the SNPs rs12917707 in <italic>UMOD</italic>, that acts as a constitutive inhibitor of calcium crystallization in renal fluids, and rs4236 in <italic>MGP</italic>, which encodes a protein acting as an inhibitor of bone formation, the associations were identified under an additive inheritance model (allelic OR&#x02009;=&#x02009;0.72, <italic>P</italic>&#x02009;=&#x02009;0.043 and allelic OR&#x02009;=&#x02009;0.75, <italic>P</italic>&#x02009;=&#x02009;0.023, respectively).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Positive associations found between candidate SNPs and chronic kidney disease (CKD) susceptibility.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Gene</th><th colspan="7">Without co-variables</th><th colspan="3">Adjusted for age and sex</th></tr><tr><th>SNP</th><th>Geno-type</th><th>Affec-ted</th><th>Un- affected</th><th>OR</th><th>95%CI</th><th><italic>P</italic></th><th>OR</th><th>95%&#x02009;CI</th><th><italic>P</italic></th></tr></thead><tbody><tr><td><italic>GPX1</italic></td><td>rs17080528</td><td>CC</td><td>211</td><td>89</td><td>1.00</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>CT</td><td>246</td><td>60</td><td>1.73</td><td>1.19&#x02013;2.52</td><td><bold>0</bold>.<bold>004</bold></td><td>1.91</td><td>1.28&#x02013;2.84</td><td><bold>0</bold>.<bold>002</bold></td></tr><tr><td/><td/><td>TT</td><td>58</td><td>15</td><td>1.63</td><td>0.88&#x02013;3.03</td><td>0.122</td><td>1.71</td><td>0.89&#x02013;3.28</td><td>0.106</td></tr><tr><td/><td/><td>T</td><td/><td/><td>1.44</td><td>1.09&#x02013;1.91</td><td><bold>0</bold>.<bold>010</bold></td><td>1.52</td><td>1.13&#x02013;2.04</td><td><bold>0</bold>.<bold>005</bold></td></tr><tr><td/><td/><td>CT&#x02009;+&#x02009;TT</td><td>304</td><td>75</td><td>1.71</td><td>1.2&#x02013;2.44</td><td><bold>0</bold>.<bold>003</bold></td><td>1.87</td><td>1.28&#x02013;2.72</td><td><bold>0</bold>.<bold>001</bold></td></tr><tr><td><italic>GSTO1</italic></td><td>rs2164624</td><td>GG</td><td>215</td><td>45</td><td>1.00</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>GA</td><td>241</td><td>98</td><td>0.51</td><td>0.35&#x02013;0.77</td><td><bold>0</bold>.<bold>001</bold></td><td>0.48</td><td>0.31&#x02013;0.73</td><td><bold>0</bold>.<bold>0005</bold></td></tr><tr><td/><td/><td>AA</td><td>71</td><td>25</td><td>0.59</td><td>0.34&#x02013;1.04</td><td>0.067</td><td>0.58</td><td>0.32&#x02013;1.05</td><td>0.071</td></tr><tr><td/><td/><td>A</td><td/><td/><td>0.72</td><td>0.55&#x02013;0.92</td><td><bold>0</bold>.<bold>010</bold></td><td>0.70</td><td>0.53&#x02013;0.91</td><td><bold>0</bold>.<bold>008</bold></td></tr><tr><td/><td/><td>GA&#x02009;+&#x02009;AA</td><td>312</td><td>123</td><td>0.53</td><td>0.36&#x02013;0.78</td><td><bold>0</bold>.<bold>001</bold></td><td>0.50</td><td>0.33&#x02013;0.75</td><td><bold>0</bold>.<bold>0007</bold></td></tr><tr><td><italic>GSTO2</italic></td><td>rs156697</td><td>AA</td><td>173</td><td>35</td><td>1.00</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>AG</td><td>254</td><td>89</td><td>0.58</td><td>0.37&#x02013;0.89</td><td><bold>0</bold>.<bold>014</bold></td><td>0.60</td><td>0.38&#x02013;0.96</td><td><bold>0</bold>.<bold>031</bold></td></tr><tr><td/><td/><td>GG</td><td>80</td><td>33</td><td>0.49</td><td>0.28&#x02013;0.85</td><td><bold>0</bold>.<bold>010</bold></td><td>0.49</td><td>0.28&#x02013;0.87</td><td><bold>0</bold>.<bold>015</bold></td></tr><tr><td/><td/><td>G</td><td/><td/><td>0.69</td><td>0.53&#x02013;0.90</td><td><bold>0</bold>.<bold>006</bold></td><td>0.70</td><td>0.53&#x02013;0.91</td><td><bold>0</bold>.<bold>008</bold></td></tr><tr><td/><td/><td>AG&#x02009;+&#x02009;GG</td><td>334</td><td>122</td><td>0.55</td><td>0.36&#x02013;0.84</td><td><bold>0</bold>.<bold>006</bold></td><td>0.57</td><td>0.37&#x02013;0.89</td><td><bold>0</bold>.<bold>013</bold></td></tr><tr><td><italic>UMOD</italic></td><td>rs12917707</td><td>GG</td><td>335</td><td>92</td><td>1.00</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>GT</td><td>156</td><td>50</td><td>0.86</td><td>0.58&#x02013;1.27</td><td>0.441</td><td>0.82</td><td>0.54&#x02013;1.24</td><td>0.344</td></tr><tr><td/><td/><td>TT</td><td>15</td><td>12</td><td>0.34</td><td>0.16&#x02013;0.76</td><td><bold>0</bold>.<bold>008</bold></td><td>0.39</td><td>0.17&#x02013;0.90</td><td><bold>0</bold>.<bold>027</bold></td></tr><tr><td/><td/><td>T</td><td/><td/><td>0.71</td><td>0.53&#x02013;0.97</td><td><bold>0</bold>.<bold>031</bold></td><td>0.72</td><td>0.52&#x02013;0.99</td><td><bold>0</bold>.<bold>043</bold></td></tr><tr><td/><td/><td>GT&#x02009;+&#x02009;TT</td><td>171</td><td>62</td><td>0.76</td><td>0.52&#x02013;1.10</td><td>0.142</td><td>0.74</td><td>0.50&#x02013;1.09</td><td>0.13</td></tr><tr><td><italic>MGP</italic></td><td>rs4236</td><td>CC</td><td>225</td><td>63</td><td>1.00</td><td/><td/><td/><td/><td/></tr><tr><td/><td/><td>CT</td><td>179</td><td>55</td><td>0.91</td><td>0.60&#x02013;1.36</td><td>0.658</td><td>0.81</td><td>0.52&#x02013;1.25</td><td>0.340</td></tr><tr><td/><td/><td>TT</td><td>84</td><td>37</td><td>0.64</td><td>0.39&#x02013;1.02</td><td>0.063</td><td>0.55</td><td>0.33&#x02013;0.91</td><td><bold>0</bold>.<bold>020</bold></td></tr><tr><td/><td/><td>T</td><td/><td/><td>0.81</td><td>0.64&#x02013;1.03</td><td>0.08</td><td>0.75</td><td>0.58&#x02013;0.96</td><td><bold>0</bold>.<bold>023</bold></td></tr><tr><td/><td/><td>CT&#x02009;+&#x02009;TT</td><td>263</td><td>92</td><td>0.80</td><td>0.55&#x02013;1.16</td><td>0.234</td><td>0.70</td><td>0.48&#x02013;1.04</td><td>0.08</td></tr></tbody></table><table-wrap-foot><p>Case-control analysis, OR, odds ratio; CI, confidence interval.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>SNPs associated with related pathologies</title><p id="Par10">It is known that patients with CKD have at the same time other diseases, which are related to the presence of renal failure, either as a cause or as a consequence. Among them we can indicate hypertension (HT), cardiovascular disease (CVD), and diabetes mellitus (DM) and, in some cases a medical history of cancer. In our study we observed a high incidence of HT (91.5%), CVD (45.2%), DM (32%), and previous cancer (30%) in patients with CKD.</p><p id="Par11">When the associations between candidate SNPs and pathologies related to CKD were considered, some associations were observed (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). For HT, two genes, <italic>GPX4</italic>, implicated in the protection of cells against oxidative damage, and <italic>CYP11B2</italic>, with the encoded enzyme catalyzing many reactions involved in drug metabolism and synthesis of cholesterol, steroids, and other lipids, showed an association in the dominant model. <italic>ERCC4</italic>, involved in nucleotide excision repair pathway, showed association in the additive model. With regard to previous cancer history, the <italic>ERCC2</italic> gene, also involved in nucleotide excision repair, showed an association under allelic model (rs13181, rs713041) and dominant model (rs1052133). For CVD we observed an association in the dominant model with the <italic>ERCC2</italic> gene.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Positive associations observed between candidate SNPs and pathologies related to chronic kidney disease (CKD), case-only analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Pathology</th><th>Gene</th><th>SNP</th><th>Genotype</th><th>No pathology<sup>&#x000a7;</sup></th><th>With pathology<sup>$</sup></th><th>OR<sup>#</sup></th><th>95%&#x02009;CI<sup>#</sup></th><th><italic>P</italic><sup><italic>#</italic></sup></th></tr></thead><tbody><tr><td rowspan="15">Hypertension</td><td rowspan="5"><bold><italic>GPX4</italic></bold></td><td>rs713041*</td><td>TT</td><td>8</td><td>190</td><td>1.00</td><td/><td/></tr><tr><td/><td>TC</td><td>14</td><td>128</td><td>0.39</td><td>0.16&#x02013;0.96</td><td><bold>0</bold>.<bold>040</bold></td></tr><tr><td/><td>CC</td><td>15</td><td>85</td><td>0.24</td><td>0.10&#x02013;0.58</td><td><bold>0</bold>.<bold>002</bold></td></tr><tr><td/><td>C</td><td/><td/><td>0.50</td><td>0.32&#x02013;0.76</td><td><bold>0</bold>.<bold>001</bold></td></tr><tr><td/><td>TC&#x02009;+&#x02009;CC</td><td>29</td><td>213</td><td>0.31</td><td>0.14&#x02013;0.70</td><td><bold>0</bold>.<bold>005</bold></td></tr><tr><td rowspan="5"><bold><italic>CYP11B2</italic></bold></td><td>rs1799998</td><td>AA</td><td>22</td><td>138</td><td>1.00</td><td/><td/></tr><tr><td/><td>AG</td><td>18</td><td>228</td><td>2.01</td><td>1.04&#x02013;3.89</td><td><bold>0</bold>.<bold>039</bold></td></tr><tr><td/><td>GG</td><td>5</td><td>105</td><td>3.63</td><td>1.23&#x02013;9.20</td><td><bold>0</bold>.<bold>018</bold></td></tr><tr><td/><td>G</td><td/><td/><td>1.89</td><td>1.19&#x02013;3.00</td><td><bold>0</bold>.<bold>007</bold></td></tr><tr><td/><td>AG&#x02009;+&#x02009;GG</td><td>23</td><td>333</td><td>2.30</td><td>1.24&#x02013;4.28</td><td><bold>0</bold>.<bold>008</bold></td></tr><tr><td rowspan="5"><bold><italic>ERCC4</italic></bold></td><td>rs3136166</td><td>TT</td><td>13</td><td>200</td><td>1.00</td><td/><td/></tr><tr><td/><td>TG</td><td>21</td><td>220</td><td>0.67</td><td>0.33&#x02013;1.38</td><td>0.281</td></tr><tr><td/><td>GG</td><td>10</td><td>46</td><td>0.29</td><td>0.12&#x02013;0.71</td><td><bold>0</bold>.<bold>007</bold></td></tr><tr><td/><td>G</td><td/><td/><td>0.55</td><td>0.35&#x02013;0.88</td><td><bold>0</bold>.<bold>011</bold></td></tr><tr><td/><td>TG&#x02009;+&#x02009;GG</td><td>31</td><td>266</td><td>0.55</td><td>0.28&#x02013;1.08</td><td>0.083</td></tr><tr><td rowspan="15">Previous cancer</td><td rowspan="5"><bold><italic>ERCC2</italic></bold></td><td>rs13181</td><td>TT</td><td>114</td><td>61</td><td>1.00</td><td/><td/></tr><tr><td/><td>TG</td><td>124</td><td>55</td><td>0.84</td><td>0.53&#x02013;1.32</td><td>0.444</td></tr><tr><td/><td>GG</td><td>39</td><td>6</td><td>0.29</td><td>0.11&#x02013;0.72</td><td><bold>0</bold>.<bold>008</bold></td></tr><tr><td/><td>G</td><td/><td/><td>0.66</td><td>0.47&#x02013;0.92</td><td><bold>0</bold>.<bold>016</bold></td></tr><tr><td/><td>TG&#x02009;+&#x02009;GG</td><td>163</td><td>61</td><td>0.70</td><td>0.45&#x02013;1.09</td><td>0.116</td></tr><tr><td rowspan="5"><bold><italic>ERCC2</italic></bold></td><td>rs713041*</td><td>TT</td><td>104</td><td>40</td><td>1.00</td><td/><td/></tr><tr><td/><td>TC</td><td>83</td><td>34</td><td>1.17</td><td>0.67&#x02013;2.03</td><td>0.584</td></tr><tr><td/><td>CC</td><td>48</td><td>33</td><td>1.87</td><td>1.03&#x02013;3.37</td><td><bold>0</bold>.<bold>038</bold></td></tr><tr><td/><td>C</td><td/><td/><td>1.35</td><td>1.01&#x02013;1.82</td><td><bold>0</bold>.<bold>046</bold></td></tr><tr><td/><td>TC&#x02009;+&#x02009;CC</td><td>131</td><td>67</td><td>1.43</td><td>0.88&#x02013;2.32</td><td>0.146</td></tr><tr><td rowspan="5"><bold><italic>ERCC2</italic></bold></td><td>rs1052133</td><td>CC</td><td>175</td><td>65</td><td>1.00</td><td/><td/></tr><tr><td/><td>CG</td><td>87</td><td>54</td><td>1.73</td><td>1.10&#x02013;2.72</td><td><bold>0</bold>.<bold>019</bold></td></tr><tr><td/><td>GG</td><td>16</td><td>3</td><td>0.63</td><td>0.17&#x02013;2.28</td><td>0.481</td></tr><tr><td/><td>G</td><td/><td/><td>1.29</td><td>0.89&#x02013;1.87</td><td>0.179</td></tr><tr><td/><td>CG&#x02009;+&#x02009;GG</td><td>103</td><td>57</td><td>0.58</td><td>1.01&#x02013;2.46</td><td><bold>0</bold>.<bold>044</bold></td></tr><tr><td rowspan="5">Cardiovascular disease</td><td rowspan="5"><bold><italic>ERCC2</italic></bold></td><td>rs1799793</td><td>TT</td><td>144</td><td>107</td><td>1.00</td><td/><td/></tr><tr><td/><td>TC</td><td>90</td><td>109</td><td>1.71</td><td>1.15&#x02013;2.54</td><td><bold>0</bold>.<bold>008</bold></td></tr><tr><td/><td>CC</td><td>26</td><td>23</td><td>1.16</td><td>0.61&#x02013;2.21</td><td>0.644</td></tr><tr><td/><td>C</td><td/><td/><td>1.28</td><td>0.96&#x02013;1.69</td><td>0.088</td></tr><tr><td/><td>TC&#x02009;+&#x02009;CC</td><td>116</td><td>132</td><td>1.58</td><td>1.09&#x02013;2.29</td><td><bold>0</bold>.<bold>016</bold></td></tr></tbody></table><table-wrap-foot><p>Case-case analysis, OR, odds ratio; CI, confidence interval.</p><p><sup>#</sup>ORs and the corresponding 95% CIs were adjusted for age and gender.</p><p><sup>$</sup>The number of genotypes may differ due to missing clinical data and/or genotypes; overall the genotype call rate was over 0.92.</p><p>*Genotype call rate for rs713041 was 0.81; both among individuals with and without the pathology.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec6"><title>SNPs associated with clinical/biochemical parameters</title><p id="Par12">CKD patients are characterized by a defined biochemical profile acting as a clinical indicator. To detect associations between the selected SNPs and clinical parameters the main analyses were done in a combined case-control population, using both logistic and linear regression models with the median or normal value as a cut-off, considering normal values according to the international system. They are used by the Puigvert Foundation, as standard protocols, and can be seen in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref> for each of the selected clinical parameters. Case-only analysis to verify the associations was done using only linear regression model. The obtained results are shown in Table&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>. As indicated, nine biochemical parameters showed any kind of statistical association with defined genes: creatinine, glomerular filtration rate, hemoglobin, erythropoietin resistance index, albumin, phosphorus, parathyroid hormone, C-reactive protein, and ferritin.</p><p id="Par13">Genetic variants codifying for antioxidant enzymes were associated with the levels of creatinine, glomerular filtration rate, erythropoietin resistance index, albumin and phosphorus levels, C-reactive protein, and ferritin levels (rs17080528 from <italic>GPX1</italic> gene, rs713041 from <italic>GPX4</italic>, rs4880 from <italic>SOD2</italic> gene, rs17880135, rs202446, rs1041740 from <italic>SOD1</italic> gene). Other genetic variants coding for phase II metabolism enzymes, were also associated with the levels of creatinine, GFR, albumin, C-reactive protein and ferritin (rs2164624 from <italic>GSTO1</italic> gene, rs156697 from <italic>GSTO2</italic> gene, rs749174 from <italic>GSTP1</italic> gene). Genetic variants of genes involved in DNA repair were strongly associated with hemoglobin and albumin levels (rs171140 from <italic>ERCC2</italic> gene) and showed borderline associations with the levels of the C-reactive protein (rs25487 for <italic>XRCC1</italic>) and phosphorus (rs3136166 from <italic>ERCC4</italic> gene). Other variants associated with renal pathology itself showed a significant relationship with the levels of creatinine, GFR, and hemoglobin, as well as RIE, PTH and C-reactive protein (rs577912, rs1207568 from <italic>KL</italic> gene, rs4236 from <italic>MGP</italic> gene, rs17319721 from <italic>SHROOM3</italic> gene, rs881858 from <italic>VEGFA</italic> gene, rs12917707 from <italic>UMOD</italic> gene, and rs12460876 from <italic>SLC7A9</italic> gene).</p><p id="Par14">Some genes related to the immune response showed a moderate association with the GFR, phosphorus and PTH levels (rs5498 from the <italic>ICAM-1</italic> gene, rs2070874 from <italic>IL-4</italic> gene, rs17561 from <italic>IL-1A</italic> gene, and rs1800797 from the <italic>IL-6</italic> gene). In addition, a variant in the gene <italic>MTHFR</italic>, related to the homocysteine synthesis, showed a moderate association with the RIE.</p><p id="Par15">Replication in the case-only setting supported the associations of the combined case-control analysis, with reduced significance for parameters, for which the cases and controls showed clearly distinct patterns, such as creatinine and glomerular filtration rate. For those parameters, a few additional associations appeared, however, with genes among the same group of antioxidant enzymes (<italic>SOD1</italic> rs1041740) and renal pathology (<italic>KL</italic> rs1204568, <italic>VEGFA</italic> rs881858) as in the combined analysis. Also for hemoglobin, two additional variants belonging to the DNA repair pathway emerged (<italic>ERCC2</italic> rs1799793, <italic>ERCC4</italic> rs3136166). For other parameters, such as erythropoietin resistance index, albumin, phosphorus, parathyroid hormone, C-reactive protein and ferritin, the associations were similar, or even stronger than in the combined analysis, due to the fact that clinical data were available mostly for cases.</p></sec></sec><sec id="Sec7" sec-type="discussion"><title>Discussion</title><p id="Par16">This study succeeded to demonstrate associations between five SNPs and CKD in the list of 38 SNPs selected in the 31 candidate genes. Genes showing associations were <italic>GPX1</italic>, <italic>GSTO1</italic>, <italic>GSTO2</italic>, <italic>UMOD</italic>, and <italic>MGP</italic>.</p><p id="Par17"><italic>GPX1</italic> is the major isoform of <italic>GPX</italic> that is expressed in the normal kidney; this accounts for 96% of kidney GPX activity and shows a protective role against oxidative stress<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Pro198Leu and Pro197Leu variants (strongly associated with our variant, LD r<sup>2</sup>&#x02009;=&#x02009;0.98) have been reported to be associated with reduction of GPX1 activity<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, and it has been suggested that <italic>GPX1</italic> is a possible candidate gene for CVD risk<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> that, as previously indicated, is a pathology strongly linked to CKD.</p><p id="Par18">Glutathione S-transferases (GSTs) are detoxification enzymes playing an important role in the conjugation of endogenous or exogenous xenobiotic toxins to glutathione (GSH). The family of cytosolic GSTs has different classes, including the Omega (GSTO) class<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Polymorphisms in <italic>GSTO1</italic> and <italic>GSTO2</italic>, members of the Omega class, might influence the level of oxidative stress<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. <italic>GSTO1</italic> (rs4925) and <italic>GSTO2</italic> (rs156697) genotypes have been associated with worse prognosis and shorter survival in bladder cancer patients<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>.</p><p id="Par19">The <italic>UMOD</italic> gene encodes for uromodulin protein acting as a constitutive inhibitor of calcium crystallization in renal fluids<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. The SNP rs12917707 was found to be associated with both glomerular filtration rate and better kidney function in two GWASs<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>. Seven SNPs of the <italic>UMOD</italic> gene that are in high LD with rs12917707 were also associated with CKD at a genome-wide significant level<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> and, in general, many studies independently corroborate earlier evidence for the association between <italic>UMOD</italic> and CKD<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.</p><p id="Par20">The <italic>MGP</italic> gene encodes a protein acting as an inhibitor of bone formation. The rs4236 variant results in a missense mutation influencing the calcification process and affecting atherosclerotic plaques<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. It is also known that the variant form is associated with a decreased quantity of coronary artery calcification<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. In this context, our results are consistent with those reported in the literature showing a protective effect with respect to CKD<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. A recent publication on the Spanish Nefrona Cohort also found the association of the rs4236 SNP of the <italic>MGP</italic> gene with CKD<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>.</p><p id="Par21">Different pathologies like hypertension, cardiovascular disease and cancer are strongly linked with CKD. Although in our study none of the genes associated with CKD were associated with these pathologies, positive associations with other candidate SNPs and genes were observed. <italic>GPX4</italic>, <italic>CYP11B2</italic>, and <italic>ERCC4</italic> genes were associated with hypertension. The phospholipid hydroperoxide GPX (GPX4) is a common intracellular selenoprotein that reduces lipid hydroperoxides and regulates leukotriene biosynthesis and cytokine signaling pathways. The SNP rs713041 causes a C to T substitution in a region of the <italic>GPX4</italic> gene corresponding to the 3&#x000b4;-untranslated region of the messenger RNA altering protein binding<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Although no association was observed in a Japanese CKD population<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>, a direct relationship between the rate of change of plasma GPX activity and the rate of change of glomerular filtration index was observed<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. <italic>The CYP11B2</italic> gene, which encodes the human aldosterone synthase, is a cytochrome P450 enzyme that catalyzes the terminal steps of aldosterone synthesis in the zona glomerulosa cells of the adrenal cortex<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. The rs1799998 polymorphism has been suggested to be associated with genetic predisposition to cardiovascular diseases, such as myocardial infarction and hypertension<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Our study agrees with those researches revealing an association with increased risk of hypertension among CKD patients<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Finally, <italic>ERCC4</italic> is involved in nucleotide excision repair (NER) pathway, with a reported association with cancer<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. This is a new finding, as no previous report found associations between this SNP and kidney diseases or hypertension.</p><p id="Par22">With regard to previous cancer history and cardiovascular disease, an association with <italic>ERCC2</italic> was observed. <italic>ERCC2</italic> is an important DNA repair gene in the NER pathway that has been associated with cancer incidence<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>, and with cardiovascular disease<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> but no previous reports linked this gene with kidney failure in humans. Nevertheless, <italic>ERCC</italic> has shown to be associated with age-related vascular dysfunction in a mouse model<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Interestingly in our study, this gene was associated with both CVD and with a previous cancer history among CKD patients.</p><p id="Par23">Since CKD is characterized by changes in clinical parameters, which in our case are continuous values, both a linear and a logistic regression model, with either the median or the normal value as a cut-off were carried out. Several associations between clinical parameters and selected SNPs were observed as indicated in Table&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>. All genes showing association with CKD showed also at least one association with the evaluated clinical parameters. <italic>GPX1</italic>, <italic>GSTO</italic>, <italic>KL</italic>, <italic>and MGP</italic> genes showed associations with the creatinine levels and with the glomerular filtration rate, which are strongly linked to CKD. In addition, <italic>GPX1</italic> and <italic>GPX4</italic> genes were also associated with phosphorus levels, <italic>GPX4</italic> with ferritin levels, <italic>GSTO</italic> with albumin levels, and <italic>KL</italic> with the resistance index to erythropoietin. The <italic>UMOD</italic> gene was associated with the levels of parathyroid hormone.</p><p id="Par24">In consonance with the large importance of cytokines in inflammatory diseases and considering that inflammation is closely related to mineral disorders in CKD<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup> we found an association between <italic>IL-4</italic> gene and phosphorus levels. We also identified an association between <italic>IL1A</italic>, <italic>IL-6</italic>, and <italic>ICAM-1</italic> genes and parathyroid hormone (PTH) values; and <italic>ICAM-1</italic> gene also with the glomerular filtration rate. Previous investigations demonstrated the effect of <italic>IL-6</italic>, <italic>IL-4</italic>, and <italic>ICAM</italic> polymorphisms in end-stage renal disease patients<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Interestingly, both cytokines (IL1A and IL-6) have been implicated as key factors linking malnutrition, accelerated atherogenesis, and excessive morbidity and mortality in end-stage renal disease (ESRD) patients in hemodialysis<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. In addition, <italic>IL-4</italic> was also associated with phosphorus levels. The same polymorphisms we evaluated for <italic>IL-4</italic> and <italic>IL-6</italic> genes were also associated with kidney function and CKD prevalence in a large Japanese population<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> where <italic>IL-4</italic> was found to be associated with glomerulonephritis<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>, and increased levels of phosphorus as well as parathyroid cell proliferation<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>, that would support our findings. Surprisingly, there was a lack of association among SNPs of <italic>IL-1</italic> and <italic>IL-6</italic> and CRP, giving the well-known relationship between CRP and inflammation. It would be interesting to analyze the possible association of these SNPs with the neutrophil-lymphocyte and platelet-lymphocyte ratio, which are considered prognostic markers associated with inflammation in many diseases including CKD, but unfortunately this information was not available.</p><p id="Par25">With regard to the selected antioxidant genes, in addition of the role of <italic>GPX</italic>, <italic>SOD</italic> genes were also associated with biomarkers such as erythropoietin resistance index, albumin and phosphorus levels, C-reactive protein and ferritin levels. These associations agree with a previous study<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, supporting the role of oxidative stress in the progression of several diseases, including CKD. Our findings also agree with previous researches showing that <italic>SOD</italic> was associated with advanced nephropathy<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>.</p><p id="Par26">Three of the genes involved in DNA repair, <italic>ERCC2</italic>, <italic>ERCC4</italic>, and <italic>XRCC1</italic> were associated with different clinical parameters. <italic>ERCC2</italic> was associated with albumin and hemoglobin levels, <italic>ERCC4</italic> with phosphorus levels, while <italic>XRCC1</italic> was associated with C-reactive protein values. <italic>ERCC</italic> genes are involved in DNA repair, in particular in the nucleotide excision repair pathway, and different SNPs have been associated with kidney pathologies such as renal cell carcinoma<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. In fact, <italic>ERCC1</italic> and <italic>ERCC4</italic> play important roles in the development of nephropathies, as demonstrated in mammalian models<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. The variant rs25487 of the <italic>XRCC1</italic> gene confers increased risk for the development of ESRD<sup><xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>.</p><p id="Par27">In our study, the <italic>GSTP1</italic> gene was associated with C-reactive protein and ferritin levels. This gene is involved in a wide range of detoxification reactions that protect cells from carcinogens<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. GSTs provide protection against reactive oxygen species and the electrophilic metabolites of carcinogens. Interestingly the role of <italic>GSTP1</italic> (together with <italic>GSTA1</italic>, <italic>GSTM1</italic>, and <italic>GSTT)</italic> genotypes was already determined in a group of end-stage renal disease patients showing that those individuals carrying the null alleles showed increased susceptibility towards oxidative and carbonyl stress<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. The Klotho (<italic>KL</italic>) gene encodes the klotho protein controlling multiple ion channels and growth factor signaling pathways, including insulin, IGF-1, and Wnt signaling.</p><p id="Par28">The Klotho gene was associated with high creatinine levels, glomerular filtration rate, and erythropoietin resistance index. <italic>KL</italic> expression in kidneys was reduced in patients with chronic renal failure<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, which would imply that the reduction of KL protein may be relevant in the pathophysiology of kidney disease. Our results would agree with those indicating a role in the increased risk observed in different pathologies associated with CKD<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>.</p><p id="Par29"><italic>SHROOM3</italic>, <italic>VEGFA</italic>, <italic>UMOD</italic>, and <italic>SLC7A9</italic>, were associated with hemoglobin and parathyroid hormone levels, with erythropoietin resistance index, with parathyroid hormone levels, and with ferritin values, respectively. Interestingly these four genes were previously associated with CKD in GWAS studies<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR68">68</xref>&#x02013;<xref ref-type="bibr" rid="CR70">70</xref></sup>. <italic>SHROOM3</italic> encodes an actin-binding protein expressed in the kidney, where it may have an important role in the morphogenesis of epithelial tissues during development<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. <italic>VEGFA</italic> encodes vascular endothelial growth factor A, and some variants have been identified related to nephrogenesis<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. <italic>UMOD</italic> encodes uromodulin which is the most abundant protein in normal urine<sup><xref ref-type="bibr" rid="CR72">72</xref></sup> having antimicrobial properties providing defense against uropathogens responsible for urinary tract infections; in addition, it may also play a role in preventing crystallization of calcium and uric acid in kidneys and urine<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. The <italic>SLC7A9</italic> gene encodes the neutral and basic amino acid transport protein (rBAT) involved in the transport of the urinary dibasic amino acids across the renal tubular membrane<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. In spite of their importance in kidney physiology, we did not find association between these genes and CKD; nevertheless, we were able to detect their modulatory role on some of the biochemical parameters that are characteristics of CKD patients. A possible explanation for the lack of association of these SNPs with CKD could be the small sample size of the control group.</p><p id="Par30">MTHFR, a folate-dependent enzyme, plays an important role in the conversion of homocysteine to methionine, being important for most of the biological processes. The variant rs1801133 of the <italic>MTHFR</italic> gene is relatively common and it has been studied for a long time. There is a wide list of disorders in different populations around the world affected by this SNP, and <italic>MTHFR</italic> variants are associated with susceptibility of type 2 diabetes mellitus in diabetic nephropathy<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. Our results showed an association between the <italic>MTHFR</italic> variant and the resistance index to the erythropoietin. Different studies show that ESRD patients homozygous for the mutant allele rs1801133 have increased mortality risk<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>, and associations of the <italic>MTHFR</italic> gene with CKD progression have also been reported<sup><xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR78">78</xref></sup>.</p><p id="Par31">A detailed discussion of the pros and cons of SNP association studies in the clinical context of CKD is outside the scope of this article, and a large number of comparisons tested may hinder the clarity of the results. Many of these studies rely on small samples, often being limited by the logistics of clinical study designs. Therefore, the ratio of the number of variables to the number of individuals/observations grows even higher, placing additional constraints on the analysis methods. An additional difficulty here lies in incorporating different data types (e.g., SNPs from different kinds of genes and metabolite measurements from metabolomics studies) into the same analysis framework, which is something that the traditional analysis using parametric statistical methods are not particularly efficient at either. Thus, small numbers of patients in some analysis, multiple variables analyzed, with possible correlation between them, are perhaps the most difficult challenge, required in this study, to associate complex variants with the CKD.</p><p id="Par32">The overall conclusion of this study is that variants in <italic>GPX1</italic>, <italic>GSTO1</italic>, <italic>GSTO2</italic>, <italic>UMOD</italic>, and <italic>MGP</italic> genes are associated with CKD. In addition, other genes were found to be associated with CKD related pathologies, such as hypertension (<italic>GPX4</italic>, <italic>CYP11B2</italic>, <italic>ERCC4</italic>), cancer predisposition (<italic>ERCC2</italic>), and cardiovascular disease (<italic>ERCC2</italic>). Finally, associations with classical CKD biochemical parameters were found for creatinine (<italic>GPX1</italic>, <italic>GSTO1</italic>, <italic>GSTO2</italic>, <italic>KL</italic>, <italic>MGP</italic>), glomerular filtration rate (<italic>GPX1</italic>, <italic>GSTO1</italic>, <italic>KL</italic>, <italic>ICAM-1</italic>, <italic>MGP</italic>), hemoglobin (<italic>ERCC2</italic>, <italic>SHROOM3</italic>), resistance index erythropoietin (<italic>SOD2</italic>, <italic>VEGFA</italic>, <italic>MTHFR</italic>, <italic>KL</italic>), albumin (<italic>SOD1</italic>, <italic>SOD2</italic>, <italic>GSTO2</italic>, <italic>ERCC2</italic>), phosphorus (<italic>IL-4</italic>, <italic>ERCC4</italic>, <italic>SOD1</italic>, <italic>GPX1</italic>, <italic>GPX4</italic>) parathyroid hormone (<italic>IL-1A</italic>, <italic>IL6</italic>, <italic>SHROOM3</italic>, <italic>UMOD</italic>, <italic>ICAM-1</italic>), C-reactive protein (<italic>SOD2</italic>, <italic>GSTP1</italic>, <italic>XRCC1</italic>), and ferritin (<italic>SOD2</italic>, <italic>GSTP1</italic>, <italic>SLC7A9</italic>, <italic>GPX4</italic>).</p></sec><sec id="Sec8"><title>Methods</title><sec id="Sec9"><title>Ethics statement</title><p id="Par33">All individuals participating in the study provided written informed consent, and blood samples were collected under protocols approved by the Ethics Committee of the Puigvert Foundation from Barcelona and Josep Trueta Hospital from Girona, in accordance with the tenets of the Declaration of Helsinki. In addition to the genotyping studies, peripheral blood samples were also used to determine standard biochemical parameters relevant for CKD.</p></sec><sec id="Sec10"><title>Study populations</title><p id="Par34">The study involved a total of 722 European-Spanish adults, including 548 patients suffering kidney pathologies at different stages, and 174 controls. All patients had a reduced glomerular filtration rate (GFR&#x02009;&#x0003c;&#x02009;60&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>). In total, we had 338 men and 210 women (62% and 38%, respectively) as CKD patients. Healthy controls were 105 men and 67 women (61% and 39%, respectively).</p><p id="Par35">General characteristics of all patients are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. In addition to the 133 patients recruited from the hospital J. Trueta (Girona), 415 patients and all controls were randomly recruited at the Puigvert Foundation, Barcelona, over a period of 7 years. Controls were selected from the urology clinic outpatients suffering from either prostatic pathology, urinary tract infections or kidney stones, and all had normal GFR, according to their ages. All controls and 415 patients belong to our previous work<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>.</p></sec><sec id="Sec11"><title>Gene and SNP selection, and genotyping</title><p id="Par36"><italic>Gene and SNP selection</italic>. A total of 38 SNPs from 31 candidate genes were selected. Some of them were previously reported in a GWAS to be associated with CKD (GLO1, <italic>SLC7A9</italic>, <italic>SHROOM3</italic>, <italic>UMOD</italic>, <italic>and VEGFA</italic>)<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR79">79</xref></sup>, other were related to pathological processes characteristic of CKD, such as cytokines (<italic>IL-1A</italic>, <italic>IL-4</italic>, <italic>IL-6</italic>, <italic>IL10</italic>, <italic>TNF-a</italic> and <italic>ICAM-1</italic>), renin-angiotensin-aldosterone system (<italic>AGT</italic> and <italic>CYP11B2</italic>), proteins involved in fibrogenesis (<italic>TGFB1</italic>), and in homocysteine synthesis (<italic>MTHFR</italic>). Some genes coding for antioxidant enzymes were also included (<italic>SOD1</italic>, <italic>SOD2</italic>, <italic>CAT</italic>, <italic>GPX1</italic>, <italic>GPX3</italic>, and <italic>GPX4</italic>). Moreover, genes involved in DNA repair pathways such as nucleotide excision repair (NER) genes (<italic>ERCC2</italic>, and <italic>ERCC4</italic>) and base excision repair (BER) genes (<italic>OGG1</italic>, <italic>MUTYH</italic>, <italic>XRCC1)</italic>, and phase-II metabolism (<italic>GSTP1</italic>, <italic>GSTO1</italic>, and <italic>GSTO2</italic>) were included. Finally, other genes related to mortality in hemodialysis patients, vascular calcification and aging (<italic>KL</italic> and <italic>MGP</italic>)<sup><xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR81">81</xref></sup> were also incorporated into the study. The gene and SNP selection were based on published studies reporting associations of SNPs with CKD, or related phenotypes, and all selected SNPs had a minor allele frequency (MAF)&#x02009;&#x0003e;&#x02009;10%. Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows details of the SNPs studied in our population. When no genotyping assay was available for the selected SNP another SNP in high linkage disequilibrium (r<sup>2</sup>&#x02009;&#x0003e;&#x02009;0.8) was genotyped instead (alternative SNPs in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par37">Genotyping was carried out using the TaqMan SNP genotyping assays (Life Technologies), according to the manufacturer&#x02019;s guidelines. To assure the genotyping reliability, repeated analysis was performed in a randomly selected 10% of samples (quality controls); no discrepancies between the genotypes were observed. KASP allelic discrimination method (LGCgenomics, Middelsex, UK) was used to genotype the SNPs rs1800896, rs1800470, rs1799793, and rs1207568. DNA amplification was performed according to the LGC genomics&#x02019; PCR conditions. Genotype detection for all SNPs was performed using a ViiA&#x02122; 7 v1.2.1 (Applied Biosystems) and allelic discrimination was performed with 95% confidence. Further information can be found in the PhD of the first author<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>.</p></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par38">For the comparison of means of the different clinical parameters, between cases and controls, the Mann Whitney test was used. For the analysis of the pathologies associated with CKD, the Fisher test was performed.</p><p id="Par39">In the association study, samples with &#x0003c;50% call rate were excluded. The observed genotype frequencies in controls were tested for Hardy-Weinberg equilibrium using the Chi-square test. Odds ratios (ORs) and 95% confidence intervals (95% CIs) for associations between genotypes and CKD, associated phenotypes and clinical parameters converted to binary variables were estimated by logistic regression while linear regression was used for continuous variables. The analyses were done considering two models, one without adjustment and a second adjusting for age and gender. Statistical significance was determined by a <italic>P</italic>-value lower than 0.05. The analyses were performed using the following statistical software: the Statistic Package of Social Sciences (SPSS) software for Windows version 19.0, PLINK 1.90, <ext-link ext-link-type="uri" xlink:href="https://www.cog-genomics.org/plink2">https://www.cog-genomics.org/plink2</ext-link>&#x02009;<sup><xref ref-type="bibr" rid="CR83">83</xref></sup> and Rx64 3.1.3 for<sup><xref ref-type="bibr" rid="CR82">82</xref></sup> Windows, <ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec13"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2019_56695_MOESM1_ESM.docx"><caption><p>Supplementary Information.</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed&#x000a0;equally: Zuray Corredor, Miguel In&#x000e1;cio da Silva Filho, Asta F&#x000f6;rsti, Ricard Marcos and Susana Pastor.</p></fn></fn-group><sec><title>Supplementary information</title><p>is available for this paper at 10.1038/s41598-019-56695-2.</p></sec><ack><title>Acknowledgements</title><p>First of all we thank all the volunteers that have participated in this study. We are grateful to Dr. Andrea Woltmann for supervising the genotyping. Corredor Z. and Rodr&#x000ed;guez-Ribera L. were supported by COLCIENCIAS (Departamento Administrativo de Ciencia Tecnolog&#x000ed;a e Innovaci&#x000f3;n de Colombia) and by a postgraduate fellowship (PIF) from the Universitat Aut&#x000f2;noma de Barcelona, respectively. The research group belongs to a consolidated Research Group (AGAUR 2009/SGR-1116) and to REDINREN (Spanish Renal Network for Research 16/06 RETICS, Instituto de Investigaci&#x000f3;n Carlos III). The results presented in this article have been included, in part, in the Doctoral Thesis of the first author (Z. Corredor). This Thesis can be consulted in the open repository of the Universitat Aut&#x000f2;noma de Barcelona. This investigation has been supported in part by a grant from Fondo de Investigaci&#x000f3;n Sanitaria (FIS, PI12/02559).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>S.P., R.M. and A.F. planned the experiments. Z.C., L.R.-R., A.V. and A.H. prepared DNA samples. I.S., J.M.D., J.B., E.C., M.V.P. and J.C.M. supplied all biological samples and information about patients. Z.C., M.I.S.F.,. and C.C., carried out the genotyping, statistical analysis and interpretation of data. S.P., R.M. and A.F. draft the manuscript. S.P., R.M., K.H. and A.F. carried out a critical revision of the manuscript. All authors approved the final version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par40">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Genetic and epigenetic factors influencing chronic kidney disease</article-title><source>Am. J. Physiol. Renal Physiol.</source><year>2014</year><volume>307</volume><fpage>757</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00306.2014</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonelli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Biomarkers of inflammation and progression of chronic kidney disease</article-title><source>Kidney Int.</source><year>2005</year><volume>68</volume><fpage>237</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00398.x</pub-id><pub-id pub-id-type="pmid">15954913</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snively</surname><given-names>CS</given-names></name></person-group><article-title>Chronic kidney disease: prevention and treatment of common complications</article-title><source>Am. Fam. Physician</source><year>2014</year><volume>70</volume><fpage>1921</fpage><lpage>1928</lpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>AI</given-names></name><etal/></person-group><article-title>Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)</article-title><source>Kidney Int.</source><year>2003</year><volume>63</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00712.x</pub-id><pub-id pub-id-type="pmid">12472787</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meguid El Nahas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chronic kidney disease: the global challenge</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)17789-7</pub-id><pub-id pub-id-type="pmid">15664230</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Chronic kidney disease as a global public health problem: approaches and initiatives -a position statement from Kidney Disease Improving Global Outcomes</article-title><source>Kidney Int.</source><year>2007</year><volume>72</volume><fpage>247</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002343</pub-id><pub-id pub-id-type="pmid">17568785</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>GM</given-names></name></person-group><article-title>Cardiovascular disease in chronic renal failure: pathophysiologic aspects</article-title><source>Semin. Dial.</source><year>2003</year><volume>16</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1046/j.1525-139X.2003.16023.x</pub-id><pub-id pub-id-type="pmid">12641870</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoval</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Genomic instability in chronic renal failure patients</article-title><source>Environ. Mol. Mutagen.</source><year>2012</year><volume>53</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1002/em.21694</pub-id><pub-id pub-id-type="pmid">22467378</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoval</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Genetic damage in chronic renal failure patients is associated with the glomerular filtration rate index</article-title><source>Mutagenesis</source><year>2010</year><volume>25</volume><fpage>603</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1093/mutage/geq047</pub-id><pub-id pub-id-type="pmid">20884684</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lialiaris</surname><given-names>T</given-names></name><etal/></person-group><article-title>Chromosome instability in patients with chronic renal failure</article-title><source>Genet. Test Mol. Biomarkers</source><year>2010</year><volume>14</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1089/gtmb.2009.0109</pub-id><pub-id pub-id-type="pmid">19929425</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffitt</surname><given-names>T</given-names></name></person-group><article-title>Oxidative DNA damage is elevated in renal patients undergoing haemodialysis</article-title><source>Open J. Prev. Med.</source><year>2014</year><volume>4</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.4236/ojpm.2014.46049</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Ribera</surname><given-names>L</given-names></name><etal/></person-group><article-title>Radiosensitivity in patients suffering from chronic kidney disease</article-title><source>In. J. Radiat. Biol.</source><year>2015</year><volume>91</volume><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.3109/09553002.2015.959670</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoyanova</surname><given-names>E</given-names></name><etal/></person-group><article-title>Base excision repair capacity in chronic renal failure patients undergoing hemodialysis treatment</article-title><source>Cell Biochem. Funct.</source><year>2014</year><volume>32</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1002/cbf.2989</pub-id><pub-id pub-id-type="pmid">23873307</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidt</surname><given-names>DG</given-names></name></person-group><article-title>Inflammation in renal disease</article-title><source>Am. J. Cardiol.</source><year>2006</year><volume>97</volume><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2005.11.012</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dungey</surname><given-names>M</given-names></name><name><surname>Hull</surname><given-names>KL</given-names></name><name><surname>Smith</surname><given-names>AC</given-names></name><name><surname>Burton</surname><given-names>JO</given-names></name><name><surname>Bishop</surname><given-names>NC</given-names></name></person-group><article-title>Inflammatory factors and exercise in chronic kidney disease</article-title><source>Int. J. Endocrinol.</source><year>2013</year><volume>2013</volume><fpage>569831</fpage><pub-id pub-id-type="doi">10.1155/2013/569831</pub-id><pub-id pub-id-type="pmid">23737775</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spittle</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Oxidative stress and inflammation in hemodialysis patients</article-title><source>Am. J. Kidney. Dis.</source><year>2001</year><volume>38</volume><fpage>1408</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2001.29280</pub-id><pub-id pub-id-type="pmid">11728983</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morena</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oxidative stress in hemodialysis patients: is NADPH oxidase complex the culprit?</article-title><source>Kidney Int.</source><year>2002</year><volume>Suppl. 80</volume><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.61.s80.20.x</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>CC</given-names></name><name><surname>Hsu</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Lin</surname><given-names>YF</given-names></name><name><surname>Wu</surname><given-names>CC</given-names></name></person-group><article-title>Oxidative stress and nucleic acid oxidation in patients with chronic kidney disease</article-title><source>Oxid. Med. Cell Longev.</source><year>2013</year><volume>2013</volume><fpage>301982</fpage><pub-id pub-id-type="doi">10.1155/2013/301982</pub-id><pub-id pub-id-type="pmid">24058721</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corredor</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Genomic damage as a biomarker of chronic kidney disease status</article-title><source>Environ. Mol. Mutagen.</source><year>2015</year><volume>56</volume><fpage>301</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1002/em.21911</pub-id><pub-id pub-id-type="pmid">25234591</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehret</surname><given-names>GB</given-names></name><etal/></person-group><article-title>Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk</article-title><source>Nature</source><year>2011</year><volume>478</volume><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/nature10405</pub-id><pub-id pub-id-type="pmid">21909115</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schunkert</surname><given-names>H</given-names></name><etal/></person-group><article-title>Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease</article-title><source>Nature Genet.</source><year>2011</year><volume>43</volume><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/ng.784</pub-id><pub-id pub-id-type="pmid">21378990</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bis</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque</article-title><source>Nature Genet.</source><year>2011</year><volume>43</volume><fpage>940</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1038/ng.920</pub-id><pub-id pub-id-type="pmid">21909108</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;ttgen</surname><given-names>A</given-names></name><etal/></person-group><article-title>New loci associated with kidney function and chronic kidney disease</article-title><source>Nature Genet.</source><year>2010</year><volume>42</volume><fpage>376</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/ng.568</pub-id><pub-id pub-id-type="pmid">20383146</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Validated SNPs for eGFR and their associations with albuminuria</article-title><source>Hum. Mol. Genet.</source><year>2012</year><volume>21</volume><fpage>3293</fpage><lpage>3298</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds138</pub-id><pub-id pub-id-type="pmid">22492995</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olden</surname><given-names>M</given-names></name><etal/></person-group><article-title>Overlap between common genetic polymorphisms underpinning kidney traits and cardiovascular disease phenotypes: the CKDGen consortium</article-title><source>Am. J. Kidney Dis.</source><year>2013</year><volume>61</volume><fpage>889</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2012.12.024</pub-id><pub-id pub-id-type="pmid">23474010</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Haan</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents paraquat and hydrogen peroxide</article-title><source>J. Biol. Chem.</source><year>1998</year><volume>273</volume><fpage>22528</fpage><lpage>22536</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.35.22528</pub-id><pub-id pub-id-type="pmid">9712879</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takata</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Genetic variation in GPX1 is associated with GPX1 activity in a comprehensive analysis of genetic variations in selenoenzyme genes and their activity and oxidative stress in humans</article-title><source>J. Nutr.</source><year>2012</year><volume>142</volume><fpage>419</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.3945/jn.111.151845</pub-id><pub-id pub-id-type="pmid">22259188</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Association of glutathione peroxidase-1 (GPx-1) rs1050450 Pro198Leu and Pro197Leu polymorphisms with cardiovascular risk: a meta-analysis of observational studies</article-title><source>J. Geriatr. Cardiol.</source><year>2014</year><volume>11</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">25009565</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JD</given-names></name><name><surname>Flanagan</surname><given-names>JU</given-names></name><name><surname>Jowsey</surname><given-names>IR</given-names></name></person-group><article-title>Glutathione transferases</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2005</year><volume>45</volume><fpage>51</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.095857</pub-id><pub-id pub-id-type="pmid">15822171</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitbread</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Characterization of the omega class of glutathione transferases</article-title><source>Methods Enzymol.</source><year>2005</year><volume>401</volume><fpage>78</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(05)01005-0</pub-id><pub-id pub-id-type="pmid">16399380</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djukic</surname><given-names>TI</given-names></name><etal/></person-group><article-title>Glutathione S-transferase T1, O1 and O2 polymorphisms are associated with survival in muscle invasive bladder cancer patients</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e74724</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0074724</pub-id><pub-id pub-id-type="pmid">24040330</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rampoldi</surname><given-names>L</given-names></name><name><surname>Scolari</surname><given-names>F</given-names></name><name><surname>Amoroso</surname><given-names>A</given-names></name><name><surname>Ghiggeri</surname><given-names>G</given-names></name><name><surname>Devuyst</surname><given-names>O</given-names></name></person-group><article-title>The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease</article-title><source>Kidney Int.</source><year>2011</year><volume>80</volume><fpage>338</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.134</pub-id><pub-id pub-id-type="pmid">21654721</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;ttgen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Multiple loci associated with indices of renal function and chronic kidney disease</article-title><source>Nature Genet.</source><year>2009</year><volume>41</volume><fpage>712</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1038/ng.377</pub-id><pub-id pub-id-type="pmid">19430482</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorski</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genome-wide association study of kidney function decline in individuals of European descent</article-title><source>Kidney Int.</source><year>2015</year><volume>87</volume><fpage>1017</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1038/ki.2014.361</pub-id><pub-id pub-id-type="pmid">25493955</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;ttgen</surname><given-names>A</given-names></name></person-group><article-title>Genome-wide association studies in nephrology research</article-title><source>Am. J. Kidney Dis.</source><year>2010</year><volume>56</volume><fpage>743</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2010.05.018</pub-id><pub-id pub-id-type="pmid">20728256</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reznichenko</surname><given-names>A</given-names></name><etal/></person-group><article-title>UMOD as a susceptibility gene for end-stage renal disease</article-title><source>BMC Med. Genet.</source><year>2012</year><volume>13</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.1186/1471-2350-13-78</pub-id><pub-id pub-id-type="pmid">22947327</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2000</year><volume>20</volume><fpage>2386</fpage><lpage>2393</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.20.11.2386</pub-id><pub-id pub-id-type="pmid">11073842</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crosier</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Matrix Gla protein polymorphisms are associated with coronary artery calcification in men</article-title><source>J. Nutr. Sci. Vitaminol. (Tokyo)</source><year>2009</year><volume>55</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.3177/jnsv.55.59</pub-id><pub-id pub-id-type="pmid">19352064</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arcidiacono</surname><given-names>T</given-names></name><etal/></person-group><article-title>Idiopathic calcium nephrolithiasis: a review of pathogenic mechanisms in the light of genetic studies</article-title><source>Am. J. Nephrol.</source><year>2014</year><volume>40</volume><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1159/000369833</pub-id><pub-id pub-id-type="pmid">25504362</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valls</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association of candidate gene polymorphisms with chronic kidney disease: results of a case-control analysis in the Nefrona Cohort</article-title><source>Front. Genet.</source><year>2019</year><volume>10</volume><fpage>118</fpage><pub-id pub-id-type="doi">10.3389/fgene.2019.00118</pub-id><pub-id pub-id-type="pmid">30863424</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bermano</surname><given-names>G</given-names></name><etal/></person-group><article-title>Evidence that a polymorphism within the 3&#x02032;UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer</article-title><source>Genes Nutr.</source><year>2007</year><volume>2</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1007/s12263-007-0052-3</pub-id><pub-id pub-id-type="pmid">18850177</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hishida</surname><given-names>A</given-names></name><etal/></person-group><article-title>Polymorphisms in genes encoding antioxidant enzymes (SOD2, CAT, GPx, TXNRD, SEPP1, SEP15 and SELS) and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study</article-title><source>J. Clin. Biochen. Nutr.</source><year>2013</year><volume>53</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.3164/jcbn.13-17</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>A</given-names></name><etal/></person-group><article-title>Glutathione peroxidase, superoxide dismutase and catalase genotypes and activities and the progression of chronic kidney disease</article-title><source>Nephrol. Dial. Transplant.</source><year>2011</year><volume>26</volume><fpage>2806</fpage><lpage>2813</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq828</pub-id><pub-id pub-id-type="pmid">21325350</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans</article-title><source>Proc. Nat. Acad. Sci. USA</source><year>1992</year><volume>89</volume><fpage>1458</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.4.1458</pub-id><pub-id pub-id-type="pmid">1741400</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delles</surname><given-names>C</given-names></name><etal/></person-group><article-title>Aldosterone synthase (CYP11B2) &#x02212;344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension</article-title><source>J. Am. Coll. Cardiol.</source><year>2001</year><volume>37</volume><fpage>878</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(00)01174-8</pub-id><pub-id pub-id-type="pmid">11693765</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension</article-title><source>J. Hum. Hypertens.</source><year>2002</year><volume>16</volume><fpage>789</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1038/sj.jhh.1001484</pub-id><pub-id pub-id-type="pmid">12444540</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>TY</given-names></name><etal/></person-group><article-title>Association between XPF polymorphisms and cancer risk: a meta-analysis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e38606</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0038606</pub-id><pub-id pub-id-type="pmid">22768293</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association between polymorphisms in ERCC2 gene and oral cancer risk: evidence from a meta-analysis</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><fpage>594</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-13-594</pub-id><pub-id pub-id-type="pmid">24330540</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altinkilic</surname><given-names>EM</given-names></name><etal/></person-group><article-title>RRM1, RRM2 and ERCC2 gene polymorphisms in coronary artery disease</article-title><source>In Vivo</source><year>2016</year><volume>30</volume><fpage>611</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">27566080</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durik</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nucleotide excision DNA repair is associated with age-related vascular dysfunction</article-title><source>Circulation</source><year>2012</year><volume>126</volume><fpage>468</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.104380</pub-id><pub-id pub-id-type="pmid">22705887</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro-Gonz&#x000e1;lez</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study</article-title><source>Clin J Am Soc Nephrol.</source><year>2009</year><volume>4</volume><issue>10</issue><fpage>1646</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.2215/CJN.02420409</pub-id><pub-id pub-id-type="pmid">19808245</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toraman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Is there a relationship between parathyroid hormone and neutrophil lymphocyte ratio or platelet lymphocyte ratio?</article-title><source>Acta Endocrinol</source><year>2019</year><volume>5</volume><fpage>96</fpage><lpage>101</lpage></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranganath</surname><given-names>P</given-names></name><name><surname>Tripathi</surname><given-names>G</given-names></name><name><surname>Sharma</surname><given-names>RK</given-names></name><name><surname>Sankhwar</surname><given-names>SN</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name></person-group><article-title>Role of non-HLA genetic variants in end-stage renal disease</article-title><source>Tissue Antigens</source><year>2009</year><volume>74</volume><fpage>147</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0039.2009.01276.x</pub-id><pub-id pub-id-type="pmid">19497039</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bologa</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients</article-title><source>Am. J. Kidney Dis.</source><year>1998</year><volume>32</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1053/ajkd.1998.v32.pm9669431</pub-id><pub-id pub-id-type="pmid">9669431</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pro-/anti-inflammatory cytokine gene polymorphisms and chronic kidney disease: a cross-sectional study</article-title><source>BMC Nephrol.</source><year>2012</year><volume>13</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1471-2369-13-2</pub-id><pub-id pub-id-type="pmid">22230215</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>RD</given-names></name><name><surname>Manchanda</surname><given-names>PK</given-names></name></person-group><article-title>Association of interleukin (IL)-4 intron-3 and IL-6 &#x02212;174 G/C gene polymorphism with susceptibility to end-stage renal disease</article-title><source>Immunogenetics</source><year>2007</year><volume>59</volume><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1007/s00251-006-0182-6</pub-id><pub-id pub-id-type="pmid">17203290</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussanne</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate</article-title><source>Eur. J. Clin. Invest.</source><year>2001</year><volume>31</volume><fpage>610</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2362.2001.00809.x</pub-id><pub-id pub-id-type="pmid">11454016</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himmelfarb</surname><given-names>J</given-names></name></person-group><article-title>Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg?</article-title><source>Semin. Dial.</source><year>2004</year><volume>17</volume><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1111/j.0894-0959.2004.17605.x</pub-id><pub-id pub-id-type="pmid">15660575</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammedi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Allelic variations in superoxide dismutase-1 (SOD1) gene are associated with increased risk of diabetic nephropathy in type 1 diabetic subjects</article-title><source>Mol. Genet. Metab.</source><year>2011</year><volume>104</volume><fpage>654</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2011.08.033</pub-id><pub-id pub-id-type="pmid">21963083</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H</given-names></name><etal/></person-group><article-title>Polymorphisms of DNA repair genes are associated with renal cell carcinoma</article-title><source>Biochem. Biophys. Res. Comm.</source><year>2006</year><volume>342</volume><fpage>1058</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.02.030</pub-id><pub-id pub-id-type="pmid">16510122</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Genotoxic stress and activation of novel DNA repair enzymes in human endothelial cells and in the retinas and kidneys of streptozotocin diabetic rats</article-title><source>Diabetes Metab. Res. Rev.</source><year>2012</year><volume>28</volume><fpage>329</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1002/dmrr.2279</pub-id><pub-id pub-id-type="pmid">22228707</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trabulus</surname><given-names>S</given-names></name><etal/></person-group><article-title>DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease</article-title><source>Mol. Biol. Rep.</source><year>2012</year><volume>39</volume><fpage>6995</fpage><lpage>7001</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-1529-8</pub-id><pub-id pub-id-type="pmid">22302399</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radwan</surname><given-names>WM</given-names></name><name><surname>Elbarbary</surname><given-names>HS</given-names></name><name><surname>Alsheikh</surname><given-names>NM</given-names></name></person-group><article-title>DNA repair genes XPD and XRCC1 polymorphisms and risk of end-stage renal disease in Egyptian population</article-title><source>Ren. Fail.</source><year>2015</year><volume>37</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.3109/0886022X.2014.967646</pub-id><pub-id pub-id-type="pmid">25310768</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis</article-title><source>Cancer Chemother. Pharmacol.</source><year>2013</year><volume>72</volume><fpage>305</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1007/s00280-013-2194-x</pub-id><pub-id pub-id-type="pmid">23695028</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suvakov</surname><given-names>S</given-names></name><etal/></person-group><article-title>Glutathione S-transferase A1, M1, P1 and T1 null or low-activity genotypes are associated with enhanced oxidative damage among haemodialysis patients</article-title><source>Nephrol. Dial. Transplant.</source><year>2013</year><volume>28</volume><fpage>202</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfs369</pub-id><pub-id pub-id-type="pmid">23034843</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>N</given-names></name><etal/></person-group><article-title>Severely reduced production of klotho in human chronic renal failure kidney</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2001</year><volume>280</volume><fpage>1015</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.4226</pub-id><pub-id pub-id-type="pmid">11162628</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>The association of Klotho polymorphism with disease progression and mortality in IgA nephropathy</article-title><source>Kidney Blood Pres. Res.</source><year>2012</year><volume>36</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1159/000343408</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Genetic loci influencing kidney function and chronic kidney disease</article-title><source>Nat. Genet.</source><year>2010</year><volume>42</volume><fpage>373</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/ng.566</pub-id><pub-id pub-id-type="pmid">20383145</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;ttgen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Uromodulin levels associate with a common UMOD variant and risk for incident CKD</article-title><source>J. Am. Soc. Nephrol.</source><year>2010</year><volume>21</volume><fpage>337</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1681/ASN.2009070725</pub-id><pub-id pub-id-type="pmid">19959715</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f6;ger</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Association of eGFR-related loci identified by GWAS with incident CKD and ESRD</article-title><source>PLoS Genet.</source><year>2011</year><volume>7</volume><fpage>e1002292</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1002292</pub-id><pub-id pub-id-type="pmid">21980298</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Le</surname><given-names>MP</given-names></name><name><surname>Wallingford</surname><given-names>JB</given-names></name></person-group><article-title>The shroom family proteins play broad roles in the morphogenesis of thickened epithelial sheets</article-title><source>Dev. Dyn.</source><year>2009</year><volume>238</volume><fpage>1480</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1002/dvdy.21942</pub-id><pub-id pub-id-type="pmid">19384856</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devuyst</surname><given-names>O</given-names></name><name><surname>Dahan</surname><given-names>K</given-names></name><name><surname>Pirson</surname><given-names>Y</given-names></name></person-group><article-title>Tamm-Horsfall protein or uromodulin: new ideas about an old molecule</article-title><source>Nephrol. Dial. Transplant.</source><year>2005</year><volume>20</volume><fpage>1290</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfh851</pub-id><pub-id pub-id-type="pmid">15840660</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlieper</surname><given-names>G</given-names></name><name><surname>Westenfeld</surname><given-names>R</given-names></name><name><surname>Brandenburg</surname><given-names>V</given-names></name><name><surname>Ketteler</surname><given-names>M</given-names></name></person-group><article-title>Inhibitors of calcification in blood and urine</article-title><source>Semin. Dial.</source><year>2007</year><volume>20</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1111/j.1525-139X.2007.00257.x</pub-id><pub-id pub-id-type="pmid">17374084</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>KA</given-names></name><etal/></person-group><article-title>The genetic diversity of cystinuria in a UK population of patients</article-title><source>BJU Int.</source><year>2015</year><volume>116</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1111/bju.12894</pub-id><pub-id pub-id-type="pmid">25109415</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>TB</given-names></name><name><surname>Drummen</surname><given-names>GP</given-names></name><name><surname>Jiang</surname><given-names>ZP</given-names></name><name><surname>Li</surname><given-names>HY</given-names></name></person-group><article-title>Methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and diabetic nephropathy susceptibility in patients with type 2 diabetes mellitus</article-title><source>Ren. Fail.</source><year>2015</year><volume>37</volume><fpage>1247</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.3109/0886022X.2015.1064743</pub-id><pub-id pub-id-type="pmid">26161693</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamison</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study</article-title><source>Am. J. Kidney Dis.</source><year>2009</year><volume>53</volume><fpage>779</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.12.023</pub-id><pub-id pub-id-type="pmid">19272686</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hishida</surname><given-names>A</given-names></name><etal/></person-group><article-title>MTHFR, MTR and MTRR polymorphisms and risk of chronic kidney disease in Japanese: cross-sectional data from the J-MICC Study</article-title><source>Int. Urol. Nephrol.</source><year>2013</year><volume>45</volume><fpage>1613</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1007/s11255-013-0432-0</pub-id><pub-id pub-id-type="pmid">23595572</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramanathan</surname><given-names>G</given-names></name><name><surname>Harichandana</surname><given-names>B</given-names></name><name><surname>Kannan</surname><given-names>S</given-names></name><name><surname>Elumalai</surname><given-names>R</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name></person-group><article-title>Association between end-stage diabetic nephropathy and MTHFR (C677T and A1298C) gene polymorphisms</article-title><source>Nephrology (Carlton)</source><year>2019</year><volume>24</volume><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1111/nep.13208</pub-id><pub-id pub-id-type="pmid">29227003</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f6;ger</surname><given-names>CA</given-names></name><name><surname>Heid</surname><given-names>IM</given-names></name></person-group><article-title>Chronic kidney disease: novel insights from genome-wide association studies</article-title><source>Kidney Blood Pres. Res.</source><year>2011</year><volume>34</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1159/000326901</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Klotho variants and chronic hemodialysis mortality</article-title><source>J. Bone Miner. Res.</source><year>2009</year><volume>24</volume><fpage>1847</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1359/jbmr.090516</pub-id><pub-id pub-id-type="pmid">19419323</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Common genetic variants of MGP are associated with calcification on the arterial wall but not with calcification present in the atherosclerotic plaques</article-title><source>Circ. Cardiovasc. Genet.</source><year>2013</year><volume>6</volume><fpage>271</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.113.000003</pub-id><pub-id pub-id-type="pmid">23677904</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="other">Corredor Marcilla, Z. F. Doctoral Thesis, Universitat Aut&#x000f2;noma de Barcelona: Da&#x000f1;o gen&#x000f3;mico como biomarcador de la enfermedad renal cr&#x000f3;nica, <ext-link ext-link-type="uri" xlink:href="http://hdl.handle.net/10803/392683">http://hdl.handle.net/10803/392683</ext-link> (2016).</mixed-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Second-generation PLINK: rising to the challenge of larger and richer datasets</article-title><source>GigaScience</source><year>2015</year><volume>4</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s13742-015-0047-8</pub-id><pub-id pub-id-type="pmid">25722852</pub-id></element-citation></ref></ref-list></back></article>